

# WOAH Reference Laboratory Reports Activities 2022

## Activities in 2022

This report has been submitted : 5 avril 2023 17:35

### Laboratory Information

<b>Name of disease (or topic) for which you are a designated WOA Reference Laboratory:</b>	Surra (Trypanosoma evansi)
<b>Address of laboratory:</b>	Nationalestraat 155, 2000 Antwerpen, BELGIUM
<b>Tel.:</b>	+32 32476371
<b>E-mail address:</b>	nvanreet@itg.be
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Dr Vet. Caroline Rombouts
<b>Name (including Title and Position) of WOA Reference Expert:</b>	Dr Van Reet Nick (Senior Researcher)
<b>Which of the following defines your laboratory? Check all that apply:</b>	Research agency

### TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CATT/T.evansi	Yes	1	248
Immune Trypanolysis	Yes	0	7
ELISA/ water soluble extract	Yes	0	4
ELISA/ RoTat 1.2 VSG	No	0	4
Direct diagnostic tests		Nationally	Internationally

Blood smear Giemsa	Yes	1	197
PCR	Yes	0	2

## TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?H?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOA?H Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOA?H MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
CATT/ T. evansi	Surra antibody detection	123 260 tests	250 tests (1 kit)	75 500 tests (302 kits of 250 reactions)	19	Africa America Asia and Pacific Europe MiddleEast
purified RoTat 1.2 VSG	Surra antibody detection	28 mg	1 mg	7 mg	3	America MiddleEast
DNA of T. evansi	Surra molecular test	1	0	50 ng	1	Asia and Pacific

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to WOA?H Members?

No

## TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

No

7. Did your laboratory validate diagnostic methods according to WOA?H Standards for the designated pathogen or disease?

No

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOA?H Standards for the designated pathogen or disease?

No

## TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA?H Members?

Yes

NAME OF WOA?H			NO. SAMPLES RECEIVED	NO. SAMPLES RECEIVED
---------------	--	--	----------------------	----------------------

MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	FOR PROVISION OF DIAGNOSTIC SUPPORT	FOR PROVISION OF CONFIRMATORY DIAGNOSES
CANADA		CATT / T. evansi	4	
CANADA		Giemsa	4	
GERMANY		CATT / T. evansi	7	
GERMANY		Giemsa	1	
GERMANY		Immune Trypanolysis		4
FRANCE		CATT / T. evansi	14	
FRANCE		Giemsa	1	
THE NETHERLANDS		CATT / T. evansi	9	
THE NETHERLANDS		Immune Trypanolysis		2
PANAMA		CATT / T. evansi	5	
PANAMA		Giemsa	5	
PORTUGAL		CATT / T. evansi	8	
PORTUGAL		Giemsa	6	
SAO TOME AND PRINCIPE		CATT / T. evansi	2	
UNITED KINGDOM		CATT / T. evansi		1
UNITED STATES OF AMERICA		CATT / T. evansi	180	
UNITED STATES OF AMERICA		Giemsa	180	
SOUTH AFRICA		Immune Trypanolysis		4
SOUTH AFRICA		ELISA / RoTat 1.2 VSG		4
SOUTH AFRICA		ELISA / water soluble extract		4
SWEDEN		CATT / T. evansi	14	
UNITED KINGDOM		PCR (TBR)		2

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
UNITED KINGDOM	Multiple requests: 1) Advice on shipment of blood samples for PCR. 2) Advise on shipment of serum for serological tests to detect surra. 3) Explanation of the diagnostic algorithm for serological tests for surra and dourine. 4) Request for documentation of the validation of CATT/T. evansi 5) Request to import T. evansi strains for biomedical research	email, zoom
THE NETHERLANDS	Advise on the use of immune trypanolysis after CATT/T.evansi positive results for dogs and	email, telephone

	horses.	
SOUTH AFRICA	Multiple requests: 1) Advise on the sensitivity and specificity of CATT/ T. evansi in horses and dogs 2) The use of immune trypanolysis after CATT/T.evansi positive results 3) Follow-up of CATT/ T. evansi seropositivity in quarantained horses 4) Use of ELISA for serological screening of surra	email
ARGENTINA	Comparison between CATT/T. evansi and ELISA using whole water soluble extracts of purified RoTat 1.2 VSG for serological screening of surra in horses	email
INDONESIA	Diagnostic algorithm to screen during an epidemic of surra in horses	email
TURKEY	Request for parasitological, serological and molecular diagnostic training for surra	email
SAUDI ARABIA	Request to assist in setup of a laboratory for serological diagnosis (ELISA, CATT/ T. evansi) for surra	email, zoom
GERMANY	Questions about the use of ELISA after a positive CATT result	email

## **TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES**

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

No

## **TOR6: EPIZOOLOGICAL DATA**

14. Did your Laboratory collect epidemiological data relevant to international disease control?

No

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

No

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

## **TOR7: SCIENTIFIC AND TECHNICAL TRAINING**

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOA H Members?

No

## **TOR8: QUALITY ASSURANCE**

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
EN ISO/IEC 17025:2017		147-TEST.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Trypanosoma evansi: CATT/T.evans	BELAC
Trypanosoma evansi: microscopy by Giemsa	BELAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

No

## **TOR9: SCIENTIFIC MEETINGS**

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOA H?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOA H?

No

## **TOR10: NETWORK WITH WOA H REFERENCE LABORATORIES**

23. Did your laboratory exchange information with other WOA H Reference Laboratories designated for the same pathogen or disease?

Yes

24. Are you a member of a network of WOA Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOA Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOA Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

## ***TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING***

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOA Reference Laboratories for the same pathogen?

No

## ***TOR12: EXPERT CONSULTANTS***

28. Did your laboratory place expert consultants at the disposal of WOA?

No

29. Additional comments regarding your report:

No